ARTICLE SUMMARY:
Medtronic’s surprising new CGM partnership with Abbott marks a potential turning point for Medtronic’s diabetes device business, but what does it mean for the diabetes market at large?
Last month, Medtronic announced a deal in the diabetes space that no one expected. The company signed an agreement to integrate Abbott’s popular Freestyle Libre continuous glucose monitoring (CGM) technology with Medtronic’s latest automated insulin delivery (AID) system, the MiniMed 780G, as well as its InPen smart insulin pen system. In doing so, Medtronic joins other US AID pump suppliers who long ago adopted a more collaborative approach to the diabetes market. Even though this is likely a one-off for Medtronic (at least in the near term), it reinforces the growing importance of partnerships in the constantly evolving diabetes device arena.
